Modern radiotherapy techniques are designed to permit reduced irradiation of healthy tissue, resulting in a diminished risk of adverse effects and shortened recovery times. Several randomized studies have demonstrated the benefits of increased dosage to the tumor bed area in combination with whole breast irradiation (WBI). Conventional WBI treatment following breast-conserving procedures, which required 5-7 weeks of daily treatments, has been reduced to 3-4 weeks when using hyperfractionated regimens. The dosage administration improves local control, albeit with poorer cosmesis. The method of accelerated partial breast irradiation (APBI) shortens the treatment period whilst reducing the irradiated volume. APBI can be delivered using intraoperative radiation, brachytherapy, or external beam radiotherapy. Currently available data support the use of external beam partial breast irradiation in selected patients. Modern radiotherapy techniques make it possible to achieve favorable cosmesis in most patients undergoing immediate breast reconstruction surgery, and studies confirm that current methods of external beam radiation allow an acceptable coverage of target volumes both in the reconstructed breast and in the regional lymphatic nodes.

Department of Oncology and Radiotherapy Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové Charles University 500 05 Hradec Králové Czech Republic

Department of Oncology Faculty of Medicine and Dentistry Palacky University and University Hospital Olomouc 779 00 Olomouc Czech Republic

Department of Radiobiology Faculty of Military Health Sciences University of Defence 500 01 Hradec Králové Czech Republic

Faculty of Health Studies Pardubice University 532 10 Pardubice Czech Republic

Oncology Centre Multiscan 532 03 Pardubice Czech Republic

Zobrazit více v PubMed

Haussmann J., Corradini S., Nestle-Kraemling C., Bölke E., Njanang F.J.D., Tamaskovics B., Orth K., Ruckhaeberle E., Fehm T., Mohrmann S., et al. Recent advances in radiotherapy of breast cancer. Radiat. Oncol. 2020;15:71. doi: 10.1186/s13014-020-01501-x. PubMed DOI PMC

Shah C., Al-Hilli Z., Vicini F. Advances in Breast Cancer Radiotherapy: Implications for Current and Future Practice. JCO Oncol. Pract. 2021;17:697–706. doi: 10.1200/OP.21.00635. PubMed DOI

Hong R., Xu B. Breast cancer: An up-to-date review and future perspectives. Cancer Commun. 2022;42:913–936. doi: 10.1002/cac2.12358. PubMed DOI PMC

Perou C.M., Sørlie T., Eisen M.B., Van De Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi: 10.1038/35021093. PubMed DOI

Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thürlimann B., Senn H.J., Panel members Strategies for subtypes--dealing with the diversity of breast cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann. Oncol. 2011;22:1736–1747. doi: 10.1093/annonc/mdr304. PubMed DOI PMC

He M.Y., Rancoule C., Rehailia-Blanchard A., Espenel S., Trone J.C., Bernichon E., Guillaume E., Vallard A., Magné N. Radiotherapy in triple-negative breast cancer: Current situation and upcoming strategies. Crit. Rev. Oncol. Hematol. 2018;131:96–101. doi: 10.1016/j.critrevonc.2018.09.004. PubMed DOI

Di Leo A., Curigliano G., Diéras V., Malorni L., Sotiriou C., Swanton C., Thompson A., Tutt A., Piccart M. New approaches for improving outcomes in breast cancer in Europe. Breast. 2015;24:321–330. doi: 10.1016/j.breast.2015.03.001. PubMed DOI

Abdulkarim B.S., Cuartero J., Hanson J., Deschênes J., Lesniak D., Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J. Clin. Oncol. 2011;29:2852–2858. doi: 10.1200/JCO.2010.33.4714. PubMed DOI PMC

Kyndi M., Sørensen F.B., Knudsen H., Overgaard M., Nielsen H.M., Overgaard J., Danish Breast Cancer Cooperative Group Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: The Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2008;26:1419–1426. doi: 10.1200/JCO.2007.14.5565. PubMed DOI

Miao K., Lei J.H., Valecha M.V., Zhang A., Xu J., Wang L., Lyu X., Chen S., Miao Z., Zhang X., et al. NOTCH1 activation compensates BRCA1 deficiency and promotes triple-negative breast cancer formation. Nat. Commun. 2020;11:3256. doi: 10.1038/s41467-020-16936-9. PubMed DOI PMC

Vrieling C., van Werkhoven E., Maingon P., Poortmans P., Weltens C., Fourquet A., Schinagl D., Oei B., Rodenhuis C.C., Horiot J.C., et al. Prognostic factors for local control in breast cancer after long-term follow-up in the EORTC Boost vs No Boost Trial: A randomized clinical trial. JAMA Oncol. 2017;3:42–48. doi: 10.1001/jamaoncol.2016.3031. PubMed DOI

Romestaing P., Lehingue Y., Carrie C., Coquard R., Montbarbon X., Ardiet J.M., Mamelle N., Gérard J.P. Role of a 10-Gy boost in the conservative treatmentof early breast cancer: Results of a randomized clinical trial in Lyon, France. J. Clin. Oncol. 1997;15:963–968. doi: 10.1200/JCO.1997.15.3.963. PubMed DOI

Bartelink H., Maingon P., Poortmans P., Weltens C., Fourquet A., Jager J., Schinagl D., Oei B., Rodenhuis C., Horiot J.C., et al. Whole-breast irradiation with or without a boost for patientst reated with breast-conserving surgery for early breast cancer: 20-yearfollow-up of a randomized phase 3 trial. Lancet Oncol. 2015;16:47–56. doi: 10.1016/S1470-2045(14)71156-8. PubMed DOI

Bartelink H., Horiot J.C., Poortmans P., Struikmans H., Van den Bogaert W., Barillot I., Fourquet A., Borger J., Jager J., Hoogenraad W., et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N. Engl. J. Med. 2001;345:1378–1387. doi: 10.1056/NEJMoa010874. PubMed DOI

Bartelink H., Horiot J.C., Poortmans P.M., Struikmans H., Van den Bogaert W., Fourquet A., Jager J.J., Hoogenraad W.J., Oei S.B., Wárlám-Rodenhuis C.C., et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J. Clin. Oncol. 2007;25:3259–3265. doi: 10.1200/JCO.2007.11.4991. PubMed DOI

Smith B.D., Bellon J.R., Blitzblau R., Freedman G., Haffty B., Hahn C., Halberg F., Hoffman K., Horst K., Moran J., et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract. Radiat. Oncol. 2018;8:145–152. doi: 10.1016/j.prro.2018.01.012. PubMed DOI

Gulstene S., Raziee H. Radiation Boost After Adjuvant Whole Breast Radiotherapy: Does Evidence Support Practice for Close Margin and Altered Fractionation? Front. Oncol. 2020;10:772. doi: 10.3389/fonc.2020.00772. PubMed DOI PMC

Hörner-Rieber J., Forster T., Hommertgen A., Haefner M.F., Arians N., König L., Harrabi S.B., Schlampp I., Weykamp F., Lischalk J.W., et al. Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial) Int. J. Radiat. Oncol. Biol. Phys. 2021;109:1311–1324. doi: 10.1016/j.ijrobp.2020.12.005. PubMed DOI

Fastner G., Krug D., Meattini I., Gruber G., Poortmans P. Expert Discussion: Hypofractionated Radiation Therapy—Standard for All Indications? Breast Care. 2022;17:224–231. doi: 10.1159/000521552. PubMed DOI PMC

Jagsi R. Progress and controversies: Radiation therapy for invasive breast cancer. CA Cancer J. Clin. 2014;64:135–152. doi: 10.3322/caac.21209. PubMed DOI

Whelan T.J., Pignol J.P., Levine M.N., Julian J.A., MacKenzie R., Parpia S., Shelley W., Grimard L., Bowen J., Lukka H., et al. Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 2010;362:513–520. doi: 10.1056/NEJMoa0906260. PubMed DOI

James M.L., Lehman M., Hider P.N., Jeffery M., Hickey B.E., Francis D.P. Fraction size in radiation treatment for breast conservation in early breast cancer. Cochrane Database Syst. Rev. 2010;11:CD003860. doi: 10.1002/14651858.CD003860.pub3. PubMed DOI

Haviland J.S., Owen J.R., Dewar J.A., Agrawal R.K., Barrett J., Barrett-Lee P.J., Dobbs H.J., Hopwood P., Lawton P.A., Magee B.J., et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14:1086–1094. doi: 10.1016/S1470-2045(13)70386-3. PubMed DOI

Meattini I., Becherini C., Boersma L., Kaidar-Person O., Marta G.N., Montero A., Offersen B.V., Aznar M.C., Belka C., Brunt A.M., et al. European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23:e21–e31. doi: 10.1016/S1470-2045(21)00539-8. PubMed DOI

Brunt A.M., Haviland J.S., Kirby A.M., Somaiah N., Wheatley D.A., Bliss J.M., Yarnold J.R. Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation. Clin. Oncol. 2021;33:430–439. doi: 10.1016/j.clon.2021.04.016. PubMed DOI

Tsang Y., Ciurlionis L., Kirby A.M., Locke I., Venables K., Yarnold J.R., Titley J., Bliss J., Coles C.E. Clinical impact of IMPORT HIGH trial (CRUK/06/003) on breast radiotherapy practices in the United Kingdom. Br. J. Radiol. 2015;88:20150453. doi: 10.1259/bjr.20150453. PubMed DOI PMC

Chen G.P., Liu F., White J., Vicini F.A., Freedman G.M., Arthur D.W., Li X.A. A planning comparison of 7 irradiation options allowed in RTOG 1005 for early-stage breast cancer. Med. Dosim. 2015;40:21–25. doi: 10.1016/j.meddos.2014.06.007. PubMed DOI PMC

Gage I., Recht A., Gelman R., Nixon A.J., Silver B., Bornstein B.A., Harris J.R. Long-term outcome following breast-conserving surgery and radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1995;33:245–251. doi: 10.1016/0360-3016(95)02001-R. PubMed DOI

Vicini F.A., Kestin L.L., Goldstein N.S. Defining the clinical target volume for patients with early-stage breast cancer treated with lumpectomy and accelerated partial breast irradiation: A pathologic analysis. Int. J. Radiat. Oncol. Biol. Phys. 2004;60:722–730. doi: 10.1016/j.ijrobp.2004.04.012. PubMed DOI

Vicini F., Shah C., Tendulkar R., Wobb J., Arthur D., Khan A., Wazer D., Keisch M. Accelerated partial breast irradiation: An update on published Level I evidence. Brachytherapy. 2016;15:607–615. doi: 10.1016/j.brachy.2016.06.007. PubMed DOI

Morrow M., White J., Moughan J., Owen J., Pajack T., Sylvester J., Wilson J.F., Winchester D. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J. Clin. Oncol. 2001;19:2254–2262. doi: 10.1200/JCO.2001.19.8.2254. PubMed DOI

Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): A randomised controlled equivalence trial. Lancet Oncol. 2013;14:1269–1277. doi: 10.1016/S1470-2045(13)70497-2. PubMed DOI

Coles C.E., Griffin C.L., Kirby A.M., Titley J., Agrawal R.K., Alhasso A., Bhattacharya I.S., Brunt A.M., Ciurlionis L., Chan C., et al. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017;390:1048–1060. doi: 10.1016/S0140-6736(17)31145-5. PubMed DOI PMC

Vaidya J.S., Wenz F., Bulsara M., Tobias J.S., Joseph D.J., Keshtgar M., Flyger H.L., Massarut S., Alvarado M., TARGIT trialists’ group et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383:603–613. doi: 10.1016/S0140-6736(13)61950-9. PubMed DOI

Livi L., Meattini I., Marrazzo L., Simontacchi G., Pallotta S., Saieva C., Paiar F., Scotti V., De Luca Cardillo C., Bastiani P., et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur. J. Cancer. 2015;51:451–463. doi: 10.1016/j.ejca.2014.12.013. PubMed DOI

Polgar C., Fodor J., Major T., Sulyok Z., Kasler M. Breast-conserving therapy with partial or whole breast irradiation: Ten-year results of the Budapest randomized trial. Radiother. Oncol. 2013;108:197–202. doi: 10.1016/j.radonc.2013.05.008. PubMed DOI

Polgar C., Major T., Fodor J., Sulyok Z., Somogyi A., Lövey K., Németh G., Kásler M. Accelerated partial-breast irradiation using high-dose-rate interstitial brachytherapy: 12-year update of a prospective clinical study. Radiother. Oncol. 2010;94:274–279. doi: 10.1016/j.radonc.2010.01.019. PubMed DOI

Shah C., Antonucci J.V., Wilkinson J.B., Wallace M., Ghilezan M., Chen P., Lewis K., Mitchell C., Vicini F. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: Results of a matched-pair analysis. Radiother. Oncol. 2011;100:210–214. doi: 10.1016/j.radonc.2011.03.011. PubMed DOI

Strnad V., Pötter R., Kovács G. Praktisches Handbuch der Brachytherapie. UNI-MED Science; Bremen, Germany: 2010.

Fentiman I.S., Poole C., Tong D., Winter P.J., Gregory W.M., Mayles H.M., Turner P., Chaudary M.A., Rubens R.D. Inadequacy of iridium implant as sole radiation treatment for operable breast cancer. Eur. J. Cancer. 1996;32A:608–611. doi: 10.1016/0959-8049(95)00639-7. PubMed DOI

Strnad V., Ott O.J., Hildebrandt G., Kauer-Dorner D., Knauerhase H., Major T., Lyczek J., Guinot J.L., Dunst J., Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO) et al. 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: A randomised, phase 3, non-inferiority trial. Lancet. 2016;387:229–238. doi: 10.1016/S0140-6736(15)00471-7. PubMed DOI

Benitez P.R., Keisch M.E., Vicini F., Stolier A., Scroggins T., Walker A., White J., Hedberg P., Hebert M., Arthur D., et al. Five-year results: The initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am. J. Surg. 2007;194:456–462. doi: 10.1016/j.amjsurg.2007.06.010. PubMed DOI

Njeh C.F., Saunders M.W., Langton C.M. Accelerated Partial Breast Irradiation (APBI): A review of available techniques. Radiat. Oncol. 2010;5:90. doi: 10.1186/1748-717X-5-90. PubMed DOI PMC

Shah C., Badiyan S., Ben Wilkinson J., Vicini F., Beitsch P., Keisch M., Arthur D., Lyden M. Treatment efficacy with accelerated partial breast irradiation (APBI): Final analysis of the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial. Ann. Surg. Oncol. 2013;20:3279–3285. doi: 10.1245/s10434-013-3158-4. PubMed DOI

Shah C., Khwaja S., Badiyan S., Wilkinson J.B., Vicini F.A., Beitsch P., Keisch M., Arthur D., Lyden M. Brachytherapy-based partial breast irradiation is associated with low rates of complications and excellent cosmesis. Brachytherapy. 2013;12:278–284. doi: 10.1016/j.brachy.2013.04.005. PubMed DOI

Vicini F.A., Chen P., Wallace M., Mitchell C., Hasan Y., Grills I., Kestin L., Schell S., Goldstein N.S., Kunzman J., et al. Interim cosmetic results and toxicity using 3D conformal external beam radiotherapy to deliver accelerated partial breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:1124–1130. doi: 10.1016/j.ijrobp.2007.04.033. PubMed DOI

NSABP B-39, RTOG 0413: A randomized phase III study of conventional whole breast irradiation versus partial breast irradiation for women with stage 0, I, or II breast cancer. Clin. Adv. Hematol. Oncol. 2006;4:719–721. PubMed

Vicini F.A., Cecchini R.S., White J.R., Arthur D.W., Julian T.B., Rabinovitch R.A., Kuske R.R., Ganz P.A., Parda D.S., Scheier M.F., et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: A randomised, phase 3, equivalence trial. Lancet. 2019;394:2155–2164. doi: 10.1016/S0140-6736(19)32514-0. PubMed DOI PMC

Whelan T.J., Julian J.A., Berrang T.S., Kim D.H., Germain I., Nichol A.M., Akra M., Lavertu S., Germain F., RAPID Trial Investigators et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): A randomised controlled trial. Lancet. 2019;394:2165–2172. doi: 10.1016/S0140-6736(19)32515-2. PubMed DOI

Polgár C., Van Limbergen E., Pötter R., Kovács G., Polo A., Lyczek J., Hildebrandt G., Niehoff P., Guinot J.L., Guedea F., et al. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) Breast Cancer Working Group based on clinical evidence (2009) Radiother. Oncol. 2010;94:264–273. doi: 10.1016/j.radonc.2010.01.014. PubMed DOI

Landis D.M., Luo W., Song J., Bellon J.R., Punglia R.S., Wong J.S., Killoran J.H., Gelman R., Harris J.R. Variability among breast radiation oncologists in delineation of the postsurgical lumpectomy cavity. Int. J. Radiat. Oncol. Biol. Phys. 2007;67:1299–1308. doi: 10.1016/j.ijrobp.2006.11.026. PubMed DOI

Petersen R.P., Truong P.T., Kader H.A., Berthelet E., Lee J.C., Hilts M.L., Kader A.S., Beckham W.A., Olivotto I.A. Target volume delineation for partial breast radiotherapy planning: Clinical characteristics associated with low interobserver concordance. Int. J. Radiat. Oncol. Biol. Phys. 2007;69:41–48. doi: 10.1016/j.ijrobp.2007.01.070. PubMed DOI

Kader H.A., Truong P.T., Pai R., Panades M., Jones S., Ansbacher W., Olivotto I.A. When is CT-based postoperative seroma most useful to plan partial breast radiotherapy? Evaluation of clinical factors affecting seroma volume and clarity. Int. J. Radiat. Oncol. Biol. Phys. 2008;72:1064–1069. doi: 10.1016/j.ijrobp.2008.02.049. PubMed DOI

Hepel J.T., Evans S.B., Hiatt J.R., Price L.L., DiPetrillo T., Wazer D.E., MacAusland S.G. Planning the breast boost: Comparison of three techniques and evolution of tumor bed during treatment. Int. J. Radiat. Oncol. Biol. Phys. 2009;74:458–463. doi: 10.1016/j.ijrobp.2008.08.051. PubMed DOI

Shah C., Vicini F., Wazer D.E., Arthur D., Patel R.R. The American Brachytherapy Society consensus statement for accelerated partial breast irradiation. Brachytherapy. 2013;12:267–277. doi: 10.1016/j.brachy.2013.02.001. PubMed DOI

Correa C., Harris E.E., Leonardi M.C., Smith B.D., Taghian A.G., Thompson A.M., White J., Harris J.R. Accelerated partial breast irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract. Radiat. Oncol. 2017;7:73–79. doi: 10.1016/j.prro.2016.09.007. PubMed DOI

Smith B.D., Arthur D.W., Buchholz T.A., Haffty B.G., Hahn C.A., Hardenbergh P.H., Julian T.B., Marks L.B., Todor D.A., Vicini F.A., et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO) Int. J. Radiat. Oncol. Biol. Phys. 2009;74:987–1001. doi: 10.1016/j.ijrobp.2009.02.031. PubMed DOI

Thomas K., Rahimi A., Spangler A., Anderson J., Garwood D. Radiation practice patterns among United States radiation oncologists for postmastectomy breast reconstruction and oncoplastic breast reduction. Pract. Radiat. Oncol. 2014;4:466–471. doi: 10.1016/j.prro.2014.04.002. PubMed DOI

Peled A.W., Foster R.D., Esserman L.J., Park C.C., Hwang E.S., Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast. Reconstr. Surg. 2012;130:503–509. doi: 10.1097/PRS.0b013e31825dbf15. PubMed DOI

Shumway D.A., Momoh A.O., Sabel M.S., Jagsi R. Integration of Breast Reconstruction and Postmastectomy Radiotherapy. J. Clin. Oncol. 2020;38:2329–2340. doi: 10.1200/JCO.19.02850. PubMed DOI

Chung E., Marsh R.B., Griffith K.A., Moran J.M., Pierce L.J. Quantifying dose to the reconstructed breast: Can we adequately treat? Med. Dosim. 2013;38:55–59. doi: 10.1016/j.meddos.2012.06.002. PubMed DOI

Ohri N., Cordeiro P.G., Keam J., Ballangrud A., Shi W., Zhang Z., Nerbun C.T., Woch K.M., Stein N.F., Zhou Y., et al. Quantifying the impact of immediate reconstruction in postmastectomy radiation: A large, dose-volume histogram-based analysis. Int. J. Radiat. Oncol. Biol. Phys. 2012;84:e153–e159. doi: 10.1016/j.ijrobp.2012.03.026. PubMed DOI

Ho A.Y., Patel N., Ohri N., Morrow M., Mehrara B.J., Disa J.J., Cordeiro P.G., Shi W., Zhang Z., Gelblum D., et al. Bilateral implant reconstruction does not affect the quality of postmastectomy radiation therapy. Med. Dosim. 2014;39:18–22. doi: 10.1016/j.meddos.2013.08.008. PubMed DOI

Kaidar-Person O., Vrou Offersen B., Hol S., Arenas M., Aristei C., Bourgier C., Cardoso M.J., Chua B., Coles C.E., Engberg Damsgaard T., et al. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiother. Oncol. 2019;137:159–166. doi: 10.1016/j.radonc.2019.04.010. PubMed DOI

Mutter R.W. ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Comment. Radiother. Oncol. 2019;141:329–330. doi: 10.1016/j.radonc.2019.07.019. PubMed DOI PMC

Darby S.C., Ewertz M., McGale P., Bennet A.M., Blom-Goldman U., Brønnum D., Correa C., Cutter D., Gagliardi G., Gigante B., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N. Engl. J. Med. 2013;368:987–998. doi: 10.1056/NEJMoa1209825. PubMed DOI

Shah C., Badiyan S., Berry S., Khan A.J., Goyal S., Schulte K., Nanavati A., Lynch M., Vicini F.A. Cardiac dose sparing and avoidance techniques in breast cancer radiotherapy. Radiother. Oncol. 2014;112:9–16. doi: 10.1016/j.radonc.2014.04.009. PubMed DOI

Catsman C.J.L.M., Beek M.A., Voogd A.C., Mulder P.G.H., Luiten E.J.T. The COSMAM TRIAL a prospective cohort study of quality of life and cosmetic outcome in patients undergoing breast conserving surgery. BMC Cancer. 2018;18:456. doi: 10.1186/s12885-018-4368-8. PubMed DOI PMC

Zwakman M., Tan A., Boersma C., Klinkenbijl J.H.G., Noorda E.M., de Jong T.R., Francken A.B. Long-term quality of life and aesthetic outcomes after breast conserving surgery in patients with breast cancer. Eur. J. Surg. Oncol. 2022;48:1692–1698. doi: 10.1016/j.ejso.2022.02.011. PubMed DOI

Exclusive Endocrine Therapy or Partial Breast Irradiation for Women Aged > 70 Years Early Stage Breast Cancer (EUROPA) [(accessed on 27 November 2022)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04134598.

Galimberti V., Cole B.F., Zurrida S., Viale G., Luini A., Veronesi P., Baratella P., Chifu C., Sargenti M., Intra M., et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297–305. doi: 10.1016/S1470-2045(13)70035-4. PubMed DOI PMC

Giuliano A.E., Hunt K.K., Ballman K.V., Beitsch P.D., Whitworth P.W., Blumencranz P.W., Leitch A.M., Saha S., McCall L.M., Morrow M. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. JAMA. 2011;305:569–575. doi: 10.1001/jama.2011.90. PubMed DOI PMC

Bartels S.A.L., Donker M., Poncet C., Sauvé N., Straver M.E., van de Velde C.J.H., Mansel R.E., Blanken C., Orzalesi L., Klinkenbijl J.H.G., et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol. 2022:JCO2201565. doi: 10.1200/JCO.22.01565. PubMed DOI

Carvalho Í.T., Rezende A.C.P., Bernardo R.J.C. Pros and cons of radiotherapy omission in elderly breast cancer patients following breast conservative surgery. Transl. Cancer Res. 2020;9((Suppl. 1)):S236–S241. doi: 10.21037/tcr.2019.10.39. PubMed DOI PMC

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) [(accessed on 27 November 2022)]; Available online: https://www.clinicaltrials.gov/ct2/show/NCT04852887.

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT) [(accessed on 27 November 2022)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03488693.

Bremer T., Whitworth P.W., Patel R., Savala J., Barry T., Lyle S., Leesman G., Linke S.P., Jirström K., Zhou W., et al. A biological signature for breast ductal carcinoma in situ to predict radiotherapy benefit and assess recurrence risk. Clin. Cancer Res. 2018;24:5895–5901. doi: 10.1158/1078-0432.CCR-18-0842. PubMed DOI

Weinmann S., Leo M.C., Francisco M., Jenkins C.L., Barry T., Leesman G., Linke S.P., Whitworth P.W., Patel R., Pellicane J., et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiation therapy. Clin. Cancer Res. 2020;26:4054–4063. doi: 10.1158/1078-0432.CCR-19-1152. PubMed DOI

Murray Brunt A., Haviland J.S., Wheatley D.A., Sydenham M.A., Alhasso A., Bloomfield D.J., Chan C., Churn M., Cleator S., Coles C.E., et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395:1613–1626. doi: 10.1016/S0140-6736(20)30932-6. PubMed DOI PMC

Coles C.E., Aristei C., Bliss J., Boersma L., Brunt A.M., Chatterjee S., Hanna G., Jagsi R., Kaidar Person O., Kirby A., et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clin. Oncol. 2020;32:279–281. doi: 10.1016/j.clon.2020.03.006. PubMed DOI PMC

Spencer K., Jones C.M., Girdler R., Roe C., Sharpe M., Lawton S., Miller L., Lewis P., Evans M., Sebag-Montefiore D., et al. The impact of the COVID-19 pandemic on radiotherapy services in England, UK: A population-based study. Lancet Oncol. 2021;22:309–320. doi: 10.1016/S1470-2045(20)30743-9. PubMed DOI PMC

Hypofractionated Radiation Therapy after Mastectomy in Preventing Recurrence in Patients with Stage IIA-IIIA Breast Cancer. [(accessed on 27 November 2022)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03414970.

Palma D.A., Olson R., Harrow S., Gaede S., Louie A.V., Haasbeek C., Mulroy L., Lock M., Rodrigues G.B., Yaremko B.P., et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 2020;38:2830–2838. doi: 10.1200/JCO.20.00818. PubMed DOI PMC

Piroth M.D., Krug D., Feyer P., Baumann R., Combs S., Duma M.N., Dunst J., Fastner G., Fietkau R., Guckenberger M., et al. Oligometastasis in breast cancer—Current status and treatment options from a radiation oncology perspective. Strahlenther. Onkol. 2022;198:601–611. doi: 10.1007/s00066-022-01938-x. PubMed DOI PMC

Guckenberger M., Baus W.W., Blanck O., Combs S.E., Debus J., Engenhart-Cabillic R., Gauer T., Grosu A.L., Schmitt D., Tanadini-Lang S., et al. Definition and quality requirements for stereotactic radiotherapy: Consensus statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery. Strahlenther. Onkol. 2020;196:417–420. doi: 10.1007/s00066-020-01603-1. PubMed DOI PMC